Home · Policy by country · Gender care in Norway

Gender care in Norway

In 2023, Norway emphatically joined the Northern European reorientation in pediatric gender care. The Norwegian Healthcare Investigation Board (Ukom) published a damning report on existing Norwegian practice and concluded that puberty blockers and cross-sex hormones in minors must be regarded as experimental. Rikshospitalet in Oslo adjusted its guidelines. Since then, hormonal treatment of Norwegian young people with gender dysphoria has been de facto limited to research contexts and exceptional cases.

The Ukom report (2023)

Statens undersøkelseskommisjon for helse- og omsorgstjenesten (Ukom), the independent Norwegian healthcare investigation agency, published a comprehensive report on pediatric gender care in March 2023. Its conclusions were sharp:

• The 2020 Norwegian national guideline was insufficiently supported by scientific evidence.
• Puberty blockers and cross-sex hormones in minors must be regarded as experimental treatments.
• Diagnostic assessment of Norwegian patients fell short; comorbid psychiatric problems were given too little weight.
• Follow-up of treated young people was inadequately arranged, so the actual treatment outcomes are unknown.
• Too little attention was paid to the risk of detransition and regret.

The report led to a shift in the Norwegian approach. Rikshospitalet in Oslo, the national reference center for pediatric gender care, adjusted its practice. Puberty blockers are no longer prescribed routinely. Hormonal interventions in minors are reserved for highly exceptional cases, preferably within clinical research.

The Helsedirektoratet and the guideline revision

The Helsedirektoratet (the Norwegian Directorate of Health) responded to the Ukom report with an announcement that the 2020 national guideline would be revised. The substantive course runs parallel to that of Sweden, Finland and Denmark: psychotherapy and treatment of comorbid problems come first, hormonal interventions require extensive multidisciplinary assessment and are only permitted in cases of severe, long-lasting dysphoria where other treatments have had insufficient effect.

Similarities with Scandinavian neighbours

With this change of course, Norway joins Sweden, Finland and Denmark. All four countries have independently — on the basis of their own scientific evaluations — reached comparable conclusions: the evidence base for hormonal treatment of minors is weak; psychotherapy must come first; comorbidity must be investigated; follow-up is essential. This convergence of independent evaluations strengthens the international credibility of the Northern European reorientation and aligns fully with the findings of the Cass Review.

Psychological care as a starting point

Under the revised Norwegian policy, young people who present with gender dysphoria are first referred to mental health care. Comorbid problems — autism, trauma, depression, eating disorders, identity confusion in adolescence — are investigated systematically. Only once it has been established that dysphoria is severe and persistent, and other treatments insufficiently effective, can a medical pathway be considered.

Legal gender change

Norway introduced a law in 2016 that allows legal sex change by self-declaration for persons from the age of sixteen. For children aged six to sixteen, parental consent is required. This legal arrangement is separate from medical policy and has remained unchanged following the tightening of pediatric gender care.